Tagged with strategy

government The national coordinator for Argentina’s ministry of health Plan Remediar discusses developing a professional management culture in the country’s public health centers, and the programs wider role in the public health system.   Would you begin by giving our readers a brief introduction to Plan Remediar, and the scope of…

strategy Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and highlights the affiliate’s emphasis on its clinical research and its impact on Argentina’s healthcare environment.   What have been some…

CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…

UAE Mohammed Zafrullah, VP & General Manager of GlaxoSmithKline (GSK) Pharmaceuticals, argues that the UAE, despite recent turmoil in the rest of the Middle East, is the perfect emerging country to do build a business in due to the many opportunities for innovation and growth.   To have a successful business,…

UAE Jan Van der Goten, GCC Managing Director of Janssen UAE, talks about his experience at Janssen GCC as regional manager, how collaboration with other companies in the industry will bring about better results for the issue of diabetes, and why this may be harder to accomplish than expected.   You…

UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late.   Our approach to…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products.  What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…

Clinical trials TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take, and explains the decision to market the drug first in China. Nemonoxacin will be the first-ever pharmaceutical developed in this…

Basic Research A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of biotech to drive the Taiwanese economy in the years to come, and Taiwan’s China connection. Participants:  Hsing-Jien Kung, President, National…

Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…

Gene Health The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well as the company’ relationship with Vita Genomics. What interested you in the genomics business, and what are your strategies for…